Ivermectin for Treatment of Mild-to-Moderate COVID-19 in the Outpatient Setting: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial

Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)-6 Study Group, Susanna Naggie
doi: https://doi.org/10.1101/2022.06.10.22276252

Data Availability

Prior to deposition of the data in a public repository which will occur when the platform trial has concluded, persons may request the data by submitting a proposal. If the data can be used for the proposed purpose and it is consistent with the informed consent, then the data will be released under a Data Use Agreement.

Back to top
Posted June 12, 2022.
Download PDF

Supplementary Material

Data/Code
Email
Ivermectin for Treatment of Mild-to-Moderate COVID-19 in the Outpatient Setting: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial
Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)-6 Study Group, Susanna Naggie
medRxiv 2022.06.10.22276252; doi: https://doi.org/10.1101/2022.06.10.22276252
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area